Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Inari Medical, Inc. INVESTOR ALERT: Kirby McInerney LLP Alerts Inari Medical, Inc. Investors of Looming Lead Plaintiff Deadline in Class Action Lawsuit

NARI

The law firm of Kirby McInerney LLP alerts investors of the fast-approaching July 12, 2024 to seek the role of lead plaintiff in a federal securities class action filed on behalf of those who acquired Inari Medical, Inc. (“Inari” or the “Company”) (NASDAQ: NARI) securities during the period of March 10, 2021 to February 28, 2024, inclusive (“the Class Period”). The firm encourages investors to contact the firm by July 12, 2024, to be appointed lead plaintiff.

[Click here to learn more about the class action]

On February 28, 2024, Inari filed its Form 10-K for the fiscal year 2023 with the U.S. Securities and Exchange Commission (“SEC”). The Company revealed in this filing that it had received a civil investigative demand from the U.S. Department of Justice in connection with an investigation under the federal Anti-Kickback Statute and Civil False Claims Act, requesting information and documents primarily relating to meals and consulting service payments provided to health care professionals. On this news, the price of Inari shares declined by $12.14 per share, or approximately 20.8%, from $58.26 per share on February 28, 2024, to close at $46.12 on February 29, 2024.

The complaint filed alleges that throughout the Class Period, Inari failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, the Company repeatedly touted Inari’s financial results and the success of its product sales but failed to disclose that these numbers were inflated by bribes and other improper and illegal payments to healthcare providers.

If you purchased or otherwise acquired Inari securities, have information, or would like to learn more about this investigation, please contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.

Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars. Additional information about the firm can be found at Kirby McInerney LLP’s website.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.



Get the latest news and updates from Stockhouse on social media

Follow STOCKHOUSE Today